-
Mashup Score: 1Invivyd (IVVD) Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC - 9 hour(s) ago
Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that new in vitro neutralization data show continued neutralizing activity of PEMGARDA™ (pemivibart) and pipeline candidate VYD2311 against dominant SARS-CoV-2 variant XEC. As anticipated based on the structural biology of pemivibart and VYD2311, the data are largely consistent with those previously reported for KP.3.1.1. The Centers for Disease Control (CDC)
Source: www.streetinsider.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0Whole Foods Market Co-founder, John Mackey, Opens Flagship Holistic Health + Wellness Club in Los Angeles - 5 month(s) ago
Love.Life redefines healthcare with one-stop destination to promote healing, optimization, vitality and community AUSTIN, Texas., Aug. 8,…
Source: www.streetinsider.comCategories: General Medicine News, Partners & KOLsTweet-
Whole Foods Market Co-founder, John Mackey, Opens Flagship Holistic Health + Wellness ... - https://t.co/KWBEctxdDo
-
-
Mashup Score: 2
Novel cardiotropic capsids transduce more than 90% of cardiomyocytes in non-human primates (NHPs) and detarget the liver and dorsal root ganglia (DRG); show safety and efficacy in a mouse model of…
Source: www.streetinsider.comCategories: General Medicine News, Rare DiseaseTweet-
Affinia Therapeutics Presents Preclinical Data for Genetic Cardiomyopathy and Sporadic ALS Programs with Novel Cardiotropic and BBB-Penetrant AAV Capsids at the American Society of Gene & Cell The https://t.co/NIRjpUYJYl via @Street_Insider
-
-
Mashup Score: 0NeuroSense Announces First Quarter 2024 Business Update - 8 month(s) ago
CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ –Â NeuroSense Therapeutics Ltd. (Nasdaq:…
Source: www.streetinsider.comCategories: General Medicine News, Rare DiseaseTweet-
NeuroSense Announces First Quarter 2024 Business Update https://t.co/7lVUf4E598 via @Street_Insider
-
-
Mashup Score: 1Ooma Office Wins PCMag 2024 Business Choice Award For VoIP Service - 9 month(s) ago
 SUNNYVALE, Calif.–(BUSINESS…
Source: www.streetinsider.comCategories: General Medicine News, General HCPsTweet-
Ooma Office Wins PCMag 2024 Business Choice Award For VoIP Service https://t.co/uiMz7Rybt6
-
-
Mashup Score: 3
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) met its primary endpoint of overall survival (OS) for the treatment of newly diagnosed patients with high-risk locally advanced cervical cancer. At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in
Source: www.streetinsider.comCategories: General Medicine News, General HCPsTweet-
KEYTRUDA Plus Chemoradiotherapy Significantly Improved OS Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer https://t.co/14JAaCG2Zz
-
-
Mashup Score: 4Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy to Treat Second Cohort in ALS Trial - 11 month(s) ago
DSMB approval to proceed to second cohort of REGALS trial (T Regulatory Cells for ALS).Ongoing Phase 1/1b study evaluating safety and efficacy of CK0803 (Neurotrophic T regulatory…
Source: www.streetinsider.comCategories: General Medicine News, Rare DiseaseTweet-
Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy to Treat Second Cohort in ALS Trial https://t.co/LhksO0VWH7 via @Street_Insider
-
-
Mashup Score: 6Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024 - 11 month(s) ago
HAMPTON, N.J., Feb. 05, 2024 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that an abstract describing 12 week results from the Companys Phase 2 clinical trial…
Source: www.streetinsider.comCategories: General Medicine News, Allergy-ImmunologyTweet-
Celldex is set to present the Phase 2 results of #Barzolvolimab in Chronic Spontaneous #Urticaria at AAAAI 2024. Stay tuned for the latest updates! #Celldex #UrticariaResearch https://t.co/K4OcWVKa8v https://t.co/KqRkc3l9xi
-
-
Mashup Score: 8ALK’s European registration application for house dust mite SLIT-tablet in young children accepted for review - 12 month(s) ago
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the European regulatory filing for ACARIZAX® (house dust mite sublingual immunotherapy tablet) in young children has been accepted for review by the…
Source: www.streetinsider.comCategories: General Medicine News, Allergy-ImmunologyTweet-
ALK's application for approval of SLIT-tablets for house dust mite allergy in young children has been accepted for review in Europe. Stay updated on the latest developments! #Allergy #Healthcare https://t.co/qZXQN5UJSW https://t.co/1W23Xs2f6b
-
-
Mashup Score: 1
Veganuary launches with ‘Vote for Veggies’ PSA voiced by Ryan Eggold, as restaurants, grocers, and food companies create special offers and promotions for January New York City, Dec. 28, 2023 (GLOBE NEWSWIRE) — FOR IMMEDIATE RELEASE What to Expect in Veganuary 2024: New Menu Items and Specials Launch Nationwide Veganuary launches with ‘Vote for Veggies’ PSA voiced by Ryan Eggold, as r estaurants, g rocers, and f ood c ompanies create special offers and promotions for January (New York City – December
Source: www.streetinsider.comCategories: General Medicine News, Partners & KOLsTweet-
What to Expect in Veganuary 2024: New Menu Items and Specials Launch Nationwide https://t.co/eEJs9eWlkS
-
In this piece I’m quoted about how Pemgarda, the preventative monoclonal antibody for COVID-19 targeted to immunocompromised individuals, remains active against the dominant XEC variant https://t.co/tbJskZNcne https://t.co/5w5LTGCUP3